Preventive effects of bexarotene and budesonide in a genetically engineered mouse model of small cell lung cancer

Yian Wang; Weidong Wen; Jun Yi; Zhongqiu Zhang; Ronald A. Lubet; Ming You

doi:10.1158/1940-6207.CAPR-09-0221

Preventive effects of bexarotene and budesonide in a genetically engineered mouse model of small cell lung cancer

Yian Wang, Weidong Wen, Jun Yi, Zhongqiu Zhang, Ronald A. Lubet, Ming You

Research output: Contribution to journal › Article › peer-review

27 Scopus citations

Abstract

In the present study, we examined the effect of bexarotene (Targretin) and budesonide in the chemoprevention of small cell lung carcinoma using a lung-specific knockout model of Rb1 and p53. Upon treatment with bexarotene, tumor incidence, number, and load were significantly reduced (P < 0.05). Budesonide treatment trended to inhibition, but the effect was not statistically significant (P > 0.05). Immunohistochemical staining indicated that bexarotene treatment decreased cell proliferation and increased apoptosis in tumors. The Rb1/ p53 gene-targeted mouse seems to be a valuable model for chemopreventive studies on human small cell lung cancer. Our results indicate that the retinoid X receptor agonist bexarotene may be a potent chemopreventive agent in this cancer type.

Original language	English (US)
Pages (from-to)	1059-1064
Number of pages	6
Journal	Cancer Prevention Research
Volume	2
Issue number	12
DOIs	https://doi.org/10.1158/1940-6207.CAPR-09-0221
State	Published - Dec 2009

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1158/1940-6207.CAPR-09-0221

Cite this

@article{7b7d1958ce9142d08988a6844aecff8e,

title = "Preventive effects of bexarotene and budesonide in a genetically engineered mouse model of small cell lung cancer",

abstract = "In the present study, we examined the effect of bexarotene (Targretin) and budesonide in the chemoprevention of small cell lung carcinoma using a lung-specific knockout model of Rb1 and p53. Upon treatment with bexarotene, tumor incidence, number, and load were significantly reduced (P < 0.05). Budesonide treatment trended to inhibition, but the effect was not statistically significant (P > 0.05). Immunohistochemical staining indicated that bexarotene treatment decreased cell proliferation and increased apoptosis in tumors. The Rb1/ p53 gene-targeted mouse seems to be a valuable model for chemopreventive studies on human small cell lung cancer. Our results indicate that the retinoid X receptor agonist bexarotene may be a potent chemopreventive agent in this cancer type.",

author = "Yian Wang and Weidong Wen and Jun Yi and Zhongqiu Zhang and Lubet, {Ronald A.} and Ming You",

year = "2009",

month = dec,

doi = "10.1158/1940-6207.CAPR-09-0221",

language = "English (US)",

volume = "2",

pages = "1059--1064",

journal = "Cancer Prevention Research",

issn = "1940-6207",

publisher = "American Association for Cancer Research Inc.",

number = "12",

}

TY - JOUR

T1 - Preventive effects of bexarotene and budesonide in a genetically engineered mouse model of small cell lung cancer

AU - Wang, Yian

AU - Wen, Weidong

AU - Yi, Jun

AU - Zhang, Zhongqiu

AU - Lubet, Ronald A.

AU - You, Ming

PY - 2009/12

Y1 - 2009/12

N2 - In the present study, we examined the effect of bexarotene (Targretin) and budesonide in the chemoprevention of small cell lung carcinoma using a lung-specific knockout model of Rb1 and p53. Upon treatment with bexarotene, tumor incidence, number, and load were significantly reduced (P < 0.05). Budesonide treatment trended to inhibition, but the effect was not statistically significant (P > 0.05). Immunohistochemical staining indicated that bexarotene treatment decreased cell proliferation and increased apoptosis in tumors. The Rb1/ p53 gene-targeted mouse seems to be a valuable model for chemopreventive studies on human small cell lung cancer. Our results indicate that the retinoid X receptor agonist bexarotene may be a potent chemopreventive agent in this cancer type.

AB - In the present study, we examined the effect of bexarotene (Targretin) and budesonide in the chemoprevention of small cell lung carcinoma using a lung-specific knockout model of Rb1 and p53. Upon treatment with bexarotene, tumor incidence, number, and load were significantly reduced (P < 0.05). Budesonide treatment trended to inhibition, but the effect was not statistically significant (P > 0.05). Immunohistochemical staining indicated that bexarotene treatment decreased cell proliferation and increased apoptosis in tumors. The Rb1/ p53 gene-targeted mouse seems to be a valuable model for chemopreventive studies on human small cell lung cancer. Our results indicate that the retinoid X receptor agonist bexarotene may be a potent chemopreventive agent in this cancer type.

UR - http://www.scopus.com/inward/record.url?scp=76549125769&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=76549125769&partnerID=8YFLogxK

U2 - 10.1158/1940-6207.CAPR-09-0221

DO - 10.1158/1940-6207.CAPR-09-0221

M3 - Article

C2 - 19934342

AN - SCOPUS:76549125769

SN - 1940-6207

VL - 2

SP - 1059

EP - 1064

JO - Cancer Prevention Research

JF - Cancer Prevention Research

IS - 12

ER -

Preventive effects of bexarotene and budesonide in a genetically engineered mouse model of small cell lung cancer

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this